Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-022641
Filing Date
2025-11-14
Accepted
2025-11-14 09:22:18
Documents
69
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1121469
2 EX-31.1 ex31-1.htm EX-31.1 8063
3 EX-31.2 ex31-2.htm EX-31.2 8167
4 EX-32.1 ex32-1.htm EX-32.1 3521
5 EX-32.2 ex32-2.htm EX-32.2 3424
6 GRAPHIC form10-q_001.jpg GRAPHIC 6476
  Complete submission text file 0001493152-25-022641.txt   5752809

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE tvgn-20250930.xsd EX-101.SCH 47276
8 XBRL CALCULATION FILE tvgn-20250930_cal.xml EX-101.CAL 54223
9 XBRL DEFINITION FILE tvgn-20250930_def.xml EX-101.DEF 265554
10 XBRL LABEL FILE tvgn-20250930_lab.xml EX-101.LAB 408738
11 XBRL PRESENTATION FILE tvgn-20250930_pre.xml EX-101.PRE 345952
71 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 756048
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE #210 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41002 | Film No.: 251481772
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)